Optimal drainage time after evacuation of chronic subdural haematoma (DRAIN TIME 2): a multicentre, randomised, multiarm and multistage non-inferiority trial in Denmark.

IF 46.5 1区 医学 Q1 CLINICAL NEUROLOGY
Lancet Neurology Pub Date : 2024-08-01 Epub Date: 2024-06-12 DOI:10.1016/S1474-4422(24)00175-3
Mads Hjortdal Grønhøj, Thorbjørn Søren Rønn Jensen, Rares Miscov, Ann Kathrine Sindby, Birgit Debrabant, Torben Hundsholt, Carsten Reidies Bjarkam, Bo Bergholt, Kåre Fugleholm, Frantz Rom Poulsen
{"title":"Optimal drainage time after evacuation of chronic subdural haematoma (DRAIN TIME 2): a multicentre, randomised, multiarm and multistage non-inferiority trial in Denmark.","authors":"Mads Hjortdal Grønhøj, Thorbjørn Søren Rønn Jensen, Rares Miscov, Ann Kathrine Sindby, Birgit Debrabant, Torben Hundsholt, Carsten Reidies Bjarkam, Bo Bergholt, Kåre Fugleholm, Frantz Rom Poulsen","doi":"10.1016/S1474-4422(24)00175-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Postoperative drainage after surgical evacuation of chronic subdural haematoma reduces the risk of recurrence, but the optimum drainage time is uncertain. We aimed to investigate the shortest possible drainage time without increasing the haematoma recurrence rate.</p><p><strong>Methods: </strong>We conducted a randomised, multi-arm and multistage non-inferiority trial at four neurosurgical centres in Denmark. We enrolled adult patients (aged ≥18 years) with symptomatic chronic subdural haematoma. All patients were treated according to the national standard practice with a burr hole above the maximum width of the haematoma. Patients were randomly assigned in a 1:1:1 ratio via a centralised web server to receive 6 h, 12 h, or 24 h of postoperative passive subdural drainage. Randomisation was done by an independent on-call neurosurgeon and was masked until 6 h after surgery. The primary outcome was symptomatic haematoma recurrence at 3 months after surgery; the rate of recurrence was assessed in a regression model for non-inferiority testing, with no missing data. Personnel assessing the primary outcome were masked to group allocation. Non-inferiority was assessed with a prespecified margin of 7%, in a modified intention-to-treat population-defined as patients with randomly assigned treatment excluding those withdrawing from study participation after randomisation, or experiencing acute rebleedings or accidental drain removal. This trial is registered with ISRCTN (number 15186366); the trial was stopped after the first interim analysis on the advice of an independent safety advisory committee.</p><p><strong>Findings: </strong>Between March 1, 2021, and June 30, 2022, 347 patients were enrolled and 331 were followed up to 3 months, 105 were assigned to 6 h of drainage, 111 to 12 h of drainage, and 115 to 24 h of drainage. At admission, 83 (25%) participants were women and 248 (75%) were men, mean age was 75·7 years (SD 10·5), median modified Rankin Scale score was 4 (IQR 3-5), and median Glasgow Coma Scale score was 15 (IQR 14-15). At 3 months after surgery, haematoma recurrence was reported in 28 (27%) of 105 patients who were assigned to 6 h drainage (predicted haematoma recurrence rate 27·0%, 95% CI 18·5 to 35·4), 22 (20%) of 111 assigned to 12 h drainage (19·5%, 12·0 to 27·0), and 12 (10%) of 115 assigned to 24 h drainage (10·4%, 4·8 to 16·0). The risk of haematoma recurrence was increased by 16·5 percentage points (95% CI 6·5 to 26·6) in patients drained for 6 h compared with 24 h, and by 9·1 percentage points (-0·4 to 18·5) in patients drained for 12 h compared with 24 h. Therefore, non-inferiority of 6 h and 12 h of drainage to 24 h of drainage was not established. 20 patients had died by 3 months, seven in the 6 h group, eight in the 12 h group, and five in the 24 h group. The most frequent known causes of death were haematoma recurrence (three in 12 h group), comorbidity (three in 12 h group), and pneumonia (one each in 6 h and 12 h groups, two in 24 h group). The most frequent complication was postoperative infection, reported in 20 (20%) patients in the 6 h group, 25 (23%) in the 12 h group, and 19 (17%) in the 24 h group. The most common infection source was the urinary tract.</p><p><strong>Interpretation: </strong>Patients surgically treated for symptomatic chronic subdural haematoma and postoperatively drained for 6 h or 12 h had higher rates of haematoma recurrence than did patients drained for 24 h. The findings from this non-inferiority trial provide evidence to support 24 h of postoperative drainage as the standard drain time when a fixed drain time approach is used. To provide solid evidence of generalisability of the results to countries other than Denmark, a multinational randomised controlled trial will be needed.</p><p><strong>Funding: </strong>None.</p>","PeriodicalId":17989,"journal":{"name":"Lancet Neurology","volume":" ","pages":"787-796"},"PeriodicalIF":46.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S1474-4422(24)00175-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Postoperative drainage after surgical evacuation of chronic subdural haematoma reduces the risk of recurrence, but the optimum drainage time is uncertain. We aimed to investigate the shortest possible drainage time without increasing the haematoma recurrence rate.

Methods: We conducted a randomised, multi-arm and multistage non-inferiority trial at four neurosurgical centres in Denmark. We enrolled adult patients (aged ≥18 years) with symptomatic chronic subdural haematoma. All patients were treated according to the national standard practice with a burr hole above the maximum width of the haematoma. Patients were randomly assigned in a 1:1:1 ratio via a centralised web server to receive 6 h, 12 h, or 24 h of postoperative passive subdural drainage. Randomisation was done by an independent on-call neurosurgeon and was masked until 6 h after surgery. The primary outcome was symptomatic haematoma recurrence at 3 months after surgery; the rate of recurrence was assessed in a regression model for non-inferiority testing, with no missing data. Personnel assessing the primary outcome were masked to group allocation. Non-inferiority was assessed with a prespecified margin of 7%, in a modified intention-to-treat population-defined as patients with randomly assigned treatment excluding those withdrawing from study participation after randomisation, or experiencing acute rebleedings or accidental drain removal. This trial is registered with ISRCTN (number 15186366); the trial was stopped after the first interim analysis on the advice of an independent safety advisory committee.

Findings: Between March 1, 2021, and June 30, 2022, 347 patients were enrolled and 331 were followed up to 3 months, 105 were assigned to 6 h of drainage, 111 to 12 h of drainage, and 115 to 24 h of drainage. At admission, 83 (25%) participants were women and 248 (75%) were men, mean age was 75·7 years (SD 10·5), median modified Rankin Scale score was 4 (IQR 3-5), and median Glasgow Coma Scale score was 15 (IQR 14-15). At 3 months after surgery, haematoma recurrence was reported in 28 (27%) of 105 patients who were assigned to 6 h drainage (predicted haematoma recurrence rate 27·0%, 95% CI 18·5 to 35·4), 22 (20%) of 111 assigned to 12 h drainage (19·5%, 12·0 to 27·0), and 12 (10%) of 115 assigned to 24 h drainage (10·4%, 4·8 to 16·0). The risk of haematoma recurrence was increased by 16·5 percentage points (95% CI 6·5 to 26·6) in patients drained for 6 h compared with 24 h, and by 9·1 percentage points (-0·4 to 18·5) in patients drained for 12 h compared with 24 h. Therefore, non-inferiority of 6 h and 12 h of drainage to 24 h of drainage was not established. 20 patients had died by 3 months, seven in the 6 h group, eight in the 12 h group, and five in the 24 h group. The most frequent known causes of death were haematoma recurrence (three in 12 h group), comorbidity (three in 12 h group), and pneumonia (one each in 6 h and 12 h groups, two in 24 h group). The most frequent complication was postoperative infection, reported in 20 (20%) patients in the 6 h group, 25 (23%) in the 12 h group, and 19 (17%) in the 24 h group. The most common infection source was the urinary tract.

Interpretation: Patients surgically treated for symptomatic chronic subdural haematoma and postoperatively drained for 6 h or 12 h had higher rates of haematoma recurrence than did patients drained for 24 h. The findings from this non-inferiority trial provide evidence to support 24 h of postoperative drainage as the standard drain time when a fixed drain time approach is used. To provide solid evidence of generalisability of the results to countries other than Denmark, a multinational randomised controlled trial will be needed.

Funding: None.

慢性硬膜下血肿排空后的最佳引流时间(DRAIN TIME 2):丹麦的一项多中心、随机、多臂和多阶段非劣效性试验。
背景:手术清除慢性硬膜下血肿后的术后引流可降低复发风险,但最佳引流时间尚不确定。我们旨在研究在不增加血肿复发率的情况下尽可能短的引流时间:我们在丹麦的四个神经外科中心开展了一项随机、多臂、多阶段的非劣效试验。我们招募了有症状的慢性硬膜下血肿成年患者(年龄≥18 岁)。所有患者都按照国家标准进行了治疗,并在血肿最大宽度上方开了一个毛细孔。患者通过中央网络服务器以1:1:1的比例随机分配接受6小时、12小时或24小时的术后硬膜下被动引流。随机分配由一名独立的值班神经外科医生完成,并在术后 6 小时前一直被蒙蔽。主要结果是术后3个月无症状血肿复发;复发率通过回归模型进行评估,以进行非劣效性测试,无数据缺失。评估主要结果的人员对组别分配进行了蒙蔽。在修改后的意向治疗人群中评估了非劣效性,预设差值为7%,意向治疗人群定义为接受随机分配治疗的患者,不包括随机分配后退出研究、急性再出血或意外拔出引流管的患者。该试验已在 ISRCTN 注册(编号 15186366);根据独立安全咨询委员会的建议,该试验在第一次中期分析后停止:2021年3月1日至2022年6月30日期间,共有347名患者入组,331名患者接受了3个月的随访,其中105名患者接受了6小时引流,111名患者接受了12小时引流,115名患者接受了24小时引流。入院时,83名(25%)参与者为女性,248名(75%)参与者为男性,平均年龄为75-7岁(SD 10-5),改良朗肯量表中位数评分为4(IQR 3-5),格拉斯哥昏迷量表中位数评分为15(IQR 14-15)。术后3个月时,105名被安排6小时引流的患者中有28人(27%)出现血肿复发(预测血肿复发率为27-0%,95% CI为18-5至35-4),111名被安排12小时引流的患者中有22人(20%)出现血肿复发(19-5%,12-0至27-0),115名被安排24小时引流的患者中有12人(10%)出现血肿复发(10-4%,4-8至16-0)。与 24 小时引流相比,6 小时引流的患者血肿复发风险增加了 16-5 个百分点(95% CI 6-5 至 26-6),12 小时引流的患者血肿复发风险增加了 9-1 个百分点(-0-4 至 18-5)。20 名患者在 3 个月后死亡,其中 6 小时组 7 人,12 小时组 8 人,24 小时组 5 人。已知最常见的死亡原因是血肿复发(12 小时组 3 例)、合并症(12 小时组 3 例)和肺炎(6 小时组和 12 小时组各 1 例,24 小时组 2 例)。最常见的并发症是术后感染,6 小时组有 20 例(20%),12 小时组有 25 例(23%),24 小时组有 19 例(17%)。最常见的感染源是尿路:这项非劣效性试验的结果提供了证据,支持在采用固定引流时间方法时,将术后引流 24 小时作为标准引流时间。为提供确凿证据证明该结果可推广到丹麦以外的国家,需要进行跨国随机对照试验:无。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Lancet Neurology
Lancet Neurology 医学-临床神经学
CiteScore
58.70
自引率
1.00%
发文量
572
审稿时长
6-12 weeks
期刊介绍: The Lancet Neurology is the world-leading clinical neurology journal. It publishes original research that advocates for change in, or sheds light on, neurological clinical practice. The topics covered include cerebrovascular disease, Alzheimer's disease and other dementias, epilepsy, migraine, neurological infections, movement disorders, multiple sclerosis, neuromuscular disorders, peripheral nerve disorders, pediatric neurology, sleep disorders, and traumatic brain injury. The journal publishes a range of article types, including Articles (including randomized clinical trials and meta-analyses), Review, Rapid Review, Comment, Correspondence, and Personal View. It also publishes Series and Commissions that aim to shape and drive positive change in clinical practice and health policy in areas of need in neurology. The Lancet Neurology is an internationally trusted source of clinical, public health, and global health knowledge. It has an Impact Factor of 48.0, making it the top-ranked clinical neurology journal out of 212 journals worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信